|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 12,161,628: Scope, Claims, and Landscape
United States Patent 12,161,628, granted on November 28, 2023, to Kura Oncology, Inc., covers crystalline forms of tipifarnib and their pharmaceutical compositions. The patent asserts broad claims over specific polymorphic forms, designated as Form A and Form B, of the active pharmaceutical ingredient (API) tipifarnib, a farnesyltransferase inhibitor. This analysis examines the patent's claims, its scope of protection, and the existing patent landscape relevant to tipifarnib.
What is the Subject Matter of Patent 12,161,628?
The patent primarily claims specific crystalline forms of tipifarnib, identified as Form A and Form B. These forms are characterized by distinct X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) data, and thermogravimetric analysis (TGA) profiles. The patent also claims pharmaceutical compositions comprising these crystalline forms, as well as methods of treating certain cancers using these compositions.
What are the Key Claims in Patent 12,161,628?
The granted claims of patent 12,161,628 define the protective scope of the invention.
-
Claim 1: This independent claim defines a specific crystalline form of tipifarnib, designated as Form A. The form is characterized by its XRPD pattern, showing specific peaks at defined 2-theta angles.
- Key XRPD Peaks for Form A: The claim lists a set of specific diffraction peaks, for example, approximately 6.1, 11.5, 17.8, 20.6, and 26.0 (± 0.2) 2-theta.
-
Claim 2: This independent claim defines another specific crystalline form of tipifarnib, designated as Form B. Similar to Claim 1, Form B is characterized by its XRPD pattern.
- Key XRPD Peaks for Form B: The claim lists a different set of specific diffraction peaks for Form B, for instance, approximately 6.8, 10.0, 13.7, 20.0, and 26.5 (± 0.2) 2-theta.
- Claim 3: This claim depends on Claim 1 and refers to a crystalline form of tipifarnib as defined in Claim 1, further characterized by its DSC profile, indicating a specific melting point or transition temperature.
- Claim 4: This claim depends on Claim 1 and refers to a crystalline form of tipifarnib as defined in Claim 1, further characterized by its TGA profile, indicating specific weight loss events at defined temperatures.
- Claim 5: This claim depends on Claim 2 and refers to a crystalline form of tipifarnib as defined in Claim 2, further characterized by its DSC profile.
- Claim 6: This claim depends on Claim 2 and refers to a crystalline form of tipifarnib as defined in Claim 2, further characterized by its TGA profile.
- Claim 7: This claim defines a pharmaceutical composition comprising a crystalline form of tipifarnib as defined in any one of claims 1-6, and a pharmaceutically acceptable carrier.
- Claim 8: This claim defines a method of treating a patient suffering from a condition for which a farnesyltransferase inhibitor is indicated, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to Claim 7.
- Claim 9: This claim depends on Claim 8 and specifies the condition as a myelodysplastic syndrome (MDS).
- Claim 10: This claim depends on Claim 8 and specifies the condition as chronic myelomonocytic leukemia (CMML).
What is the Geographic Scope of Protection?
United States Patent 12,161,628 grants exclusive rights within the United States of America. This means Kura Oncology, Inc. has the right to prevent others from making, using, selling, offering for sale, or importing the claimed crystalline forms of tipifarnib and compositions containing them within the U.S. during the patent's term. The patent term is generally 20 years from the filing date, subject to potential extensions.
What is the Market Significance of Crystalline Forms of Tipifarnib?
Tipifarnib is a small molecule inhibitor of farnesyltransferase, a key enzyme in the RAS signaling pathway. This pathway is implicated in various cancers. Kura Oncology is developing tipifarnib for the treatment of certain hematologic malignancies, including myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The development of specific, stable crystalline forms of an API is crucial for drug formulation, manufacturing, stability, and bioavailability. Different crystalline forms (polymorphs) can exhibit different physical and chemical properties, impacting drug performance.
What is the Patent Landscape for Tipifarnib?
The patent landscape for tipifarnib is characterized by a mix of composition of matter patents, formulation patents, and now, patents claiming specific crystalline forms. Kura Oncology holds key patents covering tipifarnib and its therapeutic applications.
Who are the Key Players Holding Patents Related to Tipifarnib?
- Kura Oncology, Inc.: As the assignee of patent 12,161,628, Kura Oncology is the primary holder of patents related to the specific crystalline forms of tipifarnib and its use in treating certain cancers. This includes earlier patents covering the compound itself and its therapeutic uses.
- Pfizer Inc. (formerly Parke-Davis): Pfizer was instrumental in the early development of tipifarnib (formerly known as R115777 or Zarnestra). Original composition of matter patents for tipifarnib likely originated from research conducted by or licensed from Pfizer. While Kura Oncology now holds the primary development and commercialization rights for certain indications, legacy patents from Pfizer may still be relevant or have expired.
What Other Patents Cover Tipifarnib?
Analysis of patent databases reveals other patents relevant to tipifarnib, including:
- Composition of Matter Patents: These would cover the tipifarnib molecule itself. Original patents covering the chemical entity of tipifarnib are critical foundational patents. These are likely to be expired or nearing expiration. For example, U.S. Patent 5,229,402 (originally assigned to Parke-Davis, later Pfizer) discloses farnesyltransferase inhibitors, including tipifarnib, and methods of their use. This patent expired in 2010 [1].
- Formulation Patents: Patents claiming specific pharmaceutical formulations of tipifarnib designed for improved delivery, stability, or patient compliance. These might cover particular excipients, dosage forms (e.g., tablets, capsules), or delivery mechanisms.
- Method of Use Patents: Patents claiming the use of tipifarnib for treating specific diseases or patient populations. Patent 12,161,628's claims 8-10 fall into this category, though they are tied to the specific crystalline forms.
- Process Patents: Patents covering methods of synthesizing tipifarnib or its specific crystalline forms.
How Does Patent 12,161,628 Intersect with Existing IP?
Patent 12,161,628 is a secondary patent in the lifecycle of tipifarnib. It does not cover the original composition of matter but rather specific, valuable physical forms of the API and their direct application. This type of patent is often filed to extend market exclusivity beyond the expiry of the foundational composition of matter patents, particularly when a new, improved form of the drug is developed.
- Blocking Potential Generics: By claiming specific crystalline forms, Kura Oncology can potentially block generic manufacturers from marketing their own versions of tipifarnib if those versions utilize the patented crystalline forms, even if the original composition of matter patent has expired. Generic manufacturers would need to develop non-infringing forms or seek licenses.
- Defending Market Position: This patent strengthens Kura Oncology's competitive position by providing additional layers of intellectual property protection for their tipifarnib-based drug products.
- Impact on Development of New Forms: Competitors seeking to develop generic versions of tipifarnib would need to carefully navigate this patent. They would likely aim to identify and utilize alternative, non-infringing crystalline forms or amorphous forms, or challenge the validity of patent 12,161,628.
What are the Potential Challenges to Patent 12,161,628?
As with any patent, challenges can arise based on:
- Prior Art: The existence of prior art disclosing similar crystalline forms or making them obvious at the time of invention.
- Enablement and Written Description: Whether the patent adequately describes the invention and enables a person skilled in the art to practice it.
- Novelty and Non-Obviousness: Whether the claimed crystalline forms are truly new and not an obvious variation of known compounds or forms.
- Infringement Analysis: Competitors will conduct thorough analyses to determine if their products infringe the claims.
What is the Manufacturing and Formulation Landscape?
The manufacturing and formulation of tipifarnib, particularly its crystalline forms, are critical aspects influenced by intellectual property.
What are the Manufacturing Considerations for Tipifarnib Crystalline Forms?
- Reproducibility: Manufacturing processes must reliably produce the claimed crystalline forms (Form A and Form B) with high purity and consistent physical characteristics. This requires strict control over crystallization parameters such as solvent, temperature, cooling rate, and seeding.
- Scale-Up: Processes developed in the laboratory must be scalable to commercial manufacturing volumes while maintaining the desired polymorphic form.
- Cost-Effectiveness: The manufacturing process must be economically viable for commercial production.
- Regulatory Compliance: All manufacturing processes must adhere to Good Manufacturing Practices (GMP) standards set by regulatory agencies like the FDA.
How Do Crystalline Forms Impact Formulation?
The physical properties of crystalline forms, such as solubility, dissolution rate, particle size, and stability, directly influence drug product formulation.
- Solubility and Bioavailability: Different polymorphs can have varying solubilities, which directly affects how well a drug is absorbed into the bloodstream (bioavailability). Form A and Form B are claimed to have specific advantages or characteristics that are beneficial for formulation or therapeutic efficacy.
- Stability: Crystalline forms can differ in their solid-state stability, including susceptibility to degradation, moisture uptake, and polymorphic transformation. This impacts shelf-life and storage requirements.
- Processability: Properties like flowability and compressibility are important for manufacturing solid dosage forms (tablets, capsules).
Are There Any Known Polymorphs of Tipifarnib?
The existence of patent 12,161,628 implies that specific crystalline forms of tipifarnib have been identified and characterized by Kura Oncology as novel and potentially advantageous. The claims specifically define Form A and Form B, suggesting that these are the primary focus of their IP strategy regarding solid-state forms. It is common for APIs to exhibit multiple polymorphic forms, and identifying and patenting a stable and therapeutically useful form is a standard practice in pharmaceutical development.
Key Takeaways
- United States Patent 12,161,628 protects specific crystalline forms of tipifarnib, designated as Form A and Form B, along with pharmaceutical compositions and methods of treating certain cancers using these forms.
- The patent provides Kura Oncology, Inc. with exclusive rights in the U.S. over these identified crystalline forms, extending market exclusivity beyond foundational composition of matter patents.
- The claims are precise, focusing on XRPD patterns, DSC, and TGA data to define the distinct crystalline forms.
- This patent is part of a broader IP strategy to defend tipifarnib's market position against generic competition by securing protection over specific physical manifestations of the API.
- Generic manufacturers will need to develop non-infringing crystalline forms or challenge the validity of patent 12,161,628 to market their own tipifarnib products in the U.S.
Frequently Asked Questions
1. What is the expiration date of US Patent 12,161,628?
The expiration date is determined by its filing date (typically 20 years from the earliest priority date) plus any patent term adjustments or extensions. The filing date is not explicitly stated in the patent number but can be found in the patent's official record. Assuming a typical filing date structure for a patent granted in late 2023, the patent is likely to expire around 2040-2043, before potential extensions related to regulatory review (PTE).
2. Can generic versions of tipifarnib be launched in the US if they use a different crystalline form?
Yes, if a generic manufacturer develops a tipifarnib product utilizing a crystalline form that is demonstrably different from Form A and Form B as claimed in patent 12,161,628, and this new form does not infringe any other active patents, they may be able to launch their product. However, this requires significant research and development to identify and characterize a non-infringing form and to prove its distinctiveness and non-infringement.
3. What is the significance of characterizing crystalline forms by XRPD, DSC, and TGA?
X-ray Powder Diffraction (XRPD) is used to identify the unique crystalline lattice structure of a compound, providing a fingerprint for each polymorph. Differential Scanning Calorimetry (DSC) measures thermal transitions (e.g., melting points, phase changes), revealing differences in thermal stability and energy content. Thermogravimetric Analysis (TGA) quantifies weight loss as a function of temperature, indicating the presence of solvates or hydrates. Together, these techniques provide robust evidence for distinguishing and characterizing different crystalline forms of an API.
4. Does this patent cover the therapeutic use of tipifarnib generally?
No, patent 12,161,628 specifically claims methods of treating certain cancers using a pharmaceutical composition comprising the defined crystalline forms of tipifarnib. While it covers therapeutic use, it is restricted to the context of these particular crystalline forms and compositions. General therapeutic use patents for tipifarnib may exist separately or have expired.
5. What is the role of Kura Oncology, Inc. in relation to tipifarnib?
Kura Oncology, Inc. is the current primary developer and licensor of tipifarnib for specific oncology indications. They have acquired rights and are actively pursuing clinical development and regulatory approval for tipifarnib, particularly for hematologic malignancies. Patent 12,161,628 is assigned to Kura Oncology, Inc., reflecting their investment in developing and protecting intellectual property related to the drug's improved or specific physical forms.
Citations
[1] Parke-Davis. (1993). U.S. Patent 5,229,402 A: Farnesyltransferase inhibitors. Retrieved from Google Patents
More… ↓
⤷ Start Trial
|
